- Antiplatelet agents
- Accession Number
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
Drug Drug Description Eptifibatide A peptide-based antagonist for glycoprotein IIb/IIIa used in the medical management of myocardial infarction and as an adjunct to percutaneous coronary intervention. Ticlopidine A platelet aggregation inhibitor used in the prevention of conditions associated with thrombi, such as stroke and transient ischemic attacks (TIA). Tirofiban A platelet aggregation inhibitor used to prevent thrombotic events in non-ST elevated acute coronary syndrome. Dipyridamole A phosphodiesterase inhibitor used to prevent postoperative thromboembolic events. Clopidogrel An antiplatelet agent used to prevent blood clots in peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Acetylsalicylic acid A salicylate used to treat pain, fever, inflammation, migraines, and reducing the risk of major adverse cardiovascular events. Prasugrel A P2Y12 platelet inhibitor used to reduce risk of thrombotic cardiovascular events in unstable angina or non-ST-elevation myocardial infarction (NSTEMI), and in patients with STEMI when managed with either primary or delayed PCI. Vorapaxar A platelet aggregation inhibitor used to reduce thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). Abciximab A monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention. Anagrelide A platelet-reducing agent used to treat thrombocythemia, and its related complications, secondary to myeloproliferative neoplasms. Pentoxifylline A methylxanthine derivative used to treat intermittent claudication caused by chronic occlusive arterial disease of the limbs. Iloprost A synthetic prostacyclin analog indicated to treat pulmonary arterial hypertension (PAH). Cilostazol An antiplatelet agent and vasodilator used for the symptomatic relief of intermittent claudication. Ridogrel Used as an adjunctive therapy to induce thrombolysis in patients suffering acute myocardial infarction. Sevoflurane A inhalation anaesthetic agent used for induction and maintenance of general anesthesia during surgical procedures. Epoprostenol A vasodilator and platelet aggregation inhibitor used for the management of primary pulmonary hypertension and pulmonary hypertension in patients with heart failure. Resveratrol Being investigated for the treatment of Herpes labialis infections (cold sores). Nimesulide A cyclooxygenase 2 inhibitor used to treat acute pain and primary dysmenorrhea. Defibrotide A mixture of single-stranded oligonucleotides used in the treatment of severe hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation. Beraprost For the treatment of pulmonary hypertension. Ibudilast For the treatment of multiple sclerosis, asthma, and cerebrovascular disease. Andrographolide Investigated for use/treatment in ulcerative colitis. Cangrelor A P2Y12 platelet receptor antagonist used during percutaneous coronary intervention to reduce the risk for periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST). Tranilast For the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. Triflusal A medication related to acetylsalicylic acid with antithrombotic effects used in the treatment of thromboembolic diseases. Icosapent ethyl An ethyl ester of eicosapentaenoic acid (EPA) that reduces synthesis and enhances clearance of triglycerides that is used to treat patients with severe hypertriglyceridemia. Trapidil Used in the treatment of chronic stable angina . Naftopidil Naftopidil has been investigated for the treatment of Disorder of Urinary Stent. Sarpogrelate Sarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic. Ifetroban Ifetroban has been used in trials studying the treatment of Skin Diseases, Autoimmune Diseases, Pathologic Processes, Scleroderma, Limited, and Scleroderma, Diffuse, among others. Nitroaspirin Nitroaspirin has been investigated for the treatment of Intermittent Claudication. Ketanserin Ketanserin has been investigated for the treatment of Septic Shock, Severe Sepsis, and Diabetic Foot Ulcer. Indobufen A reversible platelet aggregation inhibitor used to prevent coronary and peripheral artery occlusion. Butylphthalide Butylphthalide has been used in trials studying the prevention of Restenosis. Hydroxytyrosol Hydroxytyrosol has been used in trials studying the prevention of Breast Cancer. Ramatroban Ramatroban has been used in trials studying the treatment of Asthma. Picotamide A platelet aggregation inhibitor indicated in the treatment of myocardial infarction, thrombosis, cerebrovascular disorders, pulmonary emboli, and atherosclerosis. Cloricromen Not Annotated Linsidomine Not Annotated Buflomedil Not Annotated Relcovaptan Not Annotated Ticagrelor A P2Y12 platelet inhibitor used in patients with a history of myocardial infarction or with acute coronary syndrome (ACS) to prevent future myocardial infarction, stroke and cardiovascular death. Tesmilifene Intended for the treatment of various forms of cancer. Sulfinpyrazone A platelet inhibitory and uricosuric agent used to inhibit thrombotic and embolic processes and to manage the chronic phases of gout . Caplacizumab A von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP). 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine Not Available Bisindolylmaleimide VIII Not Available Maritime pine extract A plant extract in nutritional supplements for healthy hair, skin, and nails. Vicagrel Vicagrel is under investigation in clinical trial NCT03599284 (The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel).
- Drugs & Drug Targets